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Introduction {#sec001}
============

Dyspnea is the most common symptom in patients with acute heart failure (HF) and, as such, relief of breathlessness has been frequently employed as an end-point in clinical studies \[[@pone.0232225.ref001]\]. However, using dyspnea as an outcome variable has several limitations \[[@pone.0232225.ref001],[@pone.0232225.ref002]\]. Indeed, there is no validated dyspnea scale in patients with HF \[[@pone.0232225.ref003]\] and the use of different dyspnea questionnaires has not been standardized across studies. Moreover, previous research shows that it may be difficult to capture a meaningful change in dyspnea with the current scales available, which is consistent with the finding that dyspnea questionnaires are not interchangeable \[[@pone.0232225.ref004],[@pone.0232225.ref005]\]. Furthermore, it is worth noting that the most frequently used dyspnea scales in HF do not take into account the psychological aspects of dyspnea or its sensory quality \[[@pone.0232225.ref006]\]. As a result of the limitations of dyspnea indices in HF, many studies focusing on dyspnea relief as end-point have produced conflicting results \[[@pone.0232225.ref002],[@pone.0232225.ref003]\]. It is noteworthy that besides dyspnea questionnaires (which reflect the subjective patient sensation), there are no measurable physiological variables providing objective assessment of dyspnea in a setting of acute HF patients. Therefore, improving the tools we have to better capture the breathlessness sensation experienced by patients with acute HF would result in better characterizing patient progress and treatment.

Given that acute HF is associated with marked breathing dysfunction caused by diaphragm weakness \[[@pone.0232225.ref007]\], assessing the functional activity of respiratory muscles might provide useful information on the degree of dyspnea severity in HF patients. Indeed, it was early reported that HF patients had abnormally low values of maximum inspiratory pressure and impaired diaphragm contractibility and that these diaphragm alterations correlated with dyspnea perception and were associated with worse overall prognosis \[[@pone.0232225.ref008]--[@pone.0232225.ref010]\]. The concept that surface electromyography (EMG) of respiratory muscles correlates with the intensity of dyspnea has been already proved in patients with no HF but also presenting dyspnea as predominant symptom: mechanical ventilation \[[@pone.0232225.ref011],[@pone.0232225.ref012]\] and chronic obstructive pulmonary disease (COPD) \[[@pone.0232225.ref013],[@pone.0232225.ref014]\]. Accordingly, it is plausible to expect that similar results could be observed in HF patients. However, whether respiratory muscles EMG is correlated with dyspnea in acute HF patients is unknown. Thus, the aim of this study was to test the hypothesis that, in a clinical setting of acute HF, surface EMG of the patient's respiratory muscles correlates with the dyspnea scores conventionally assessed by using a clinical scale, potentially providing a non-invasive objective index helping to monitor patient breathlessness.

Methods {#sec002}
=======

Patients {#sec003}
--------

This prospective and descriptive pilot study was carried out in adult patients (\>18 year old) admitted for acute HF at the Cardiology Department of the Hospital del Mar between August 2017 and September 2018. HF diagnosis and treatment was established according to the ESC HF Guidelines \[[@pone.0232225.ref015]\] and the investigation conformed to the principles outlined in the Declaration of Helsinki. Patients were included within the first 24 hours of admission and after obtaining their written informed consent to participate in the study, which was approved by the Hospital del Mar Ethical Committee (number 2017/7161/I). Patients with the following conditions were excluded: need for invasive or non-invasive mechanical ventilation, need for inotropic drugs, pacemaker-dependent, presence of other causes of acute dyspnea (e.g. decompensated COPD, pneumonia), metastatic active neoplasm or impossibility to give informed consent (e.g. low level of consciousness, moderate/severe cognitive impairment, and important language barrier).

Protocol {#sec004}
--------

Demographic and anthropometric data were collected. A first measurement was carried out within 24 h after hospital arrival. Clinical data (blood pressure, heart rate, spontaneous breath rate, oxygen saturation, weight) were recorded. To perform the EMG measurement, the patient was instrumented with a cardiorespiratory portable polygraph (Sleep&Go, Sibelmed, Spain) including nasal prongs to indirectly assess ventilation, pulse oximetry and surface EMG. To measure the activity of the main (diaphragm) and accessory (scalene and pectoralis minor) respiratory muscles we used 6 surface electrodes (Neuroline 715, Ambu, Copenhagen), a pair for each muscle ([Fig 1](#pone.0232225.g001){ref-type="fig"}). A ground electrode (Neuroline Ground, Ambu, Copenhagen) was placed on the right arm. All surface electrodes were placed on the patient's right side. The scalene electrode pair was placed in the posterior triangle of the neck between the sternocleidomastoid muscle and the clavicle, the pectoralis minor electrode pair was placed in the second intercostal space, close to the sternum and the diaphragm electrode pair was placed in the seventh or eighth intercostal space at the mid-clavicular line ([Fig 1](#pone.0232225.g001){ref-type="fig"}). After the sensors were in place, the patient was allowed to relax and stabilize his/her breathing sensation for a few minutes in sitting or semi-recumbent posture and was asked about his/her dyspnea sensation by means of the conventional Likert 5 questionnaire (score 1 = not at all short of breath, score 2 = mildly short of breath, score 3 = moderately short of breath, score 4 = severely short of breath, score 5 = worst possible short of breath). Then, the patient was instructed not to move or talk, and sensors data recording was started. After 3 min of spontaneous breathing the patient was asked to breathe at maximum effort for several cycles, data recording was subsequently stopped, and the measurement finished after the patient was freed from the EMG electrodes. The same measurement procedure was repeated along hospital admission at day 2 and day 5 or the day of discharge, whichever came first.

![Diagram of the measurement setting in heart failure patients.\
Noninvasive electromyography (EMG) of respiratory muscles was assessed by surface electrodes. EMG signals and breathing flow indirectly sensed by a nasal cannula were recorded by a portable respiratory polygraph for subsequent data processing.](pone.0232225.g001){#pone.0232225.g001}

EMG data processing {#sec005}
-------------------

The clinicians performing the measurements on patients were blinded to the EMG data, which were analyzed offline following patient discharge. The EMG signals downloaded from the polygraph ([Fig 2](#pone.0232225.g002){ref-type="fig"}) were first processed to detect and remove the QRS complex. To this end, the position of the R peak in the QRS complex was detected by using the specialized Pan-Tompkins algorithm \[[@pone.0232225.ref016]\], and the QRS component was removed and replaced by the vicinity moving average values of the signal. Subsequently, the signal was rectified to compute the mean amplitude of the EMG signal which is the most commonly used single variable to capture respiratory muscles activity in similar settings \[[@pone.0232225.ref011], [@pone.0232225.ref012]\]. Then, an index to quantify the activity of each respiratory muscle and measurement time was computed from the amplitude of the EMG data. This process was simultaneously applied to the EMG signals recorded in the 3 muscles, for periods including at least 3 breathing cycles during both spontaneous breathing and maximal breathing effort. To limit the major sources of variability in the amplitude of EMG signals -which is mainly caused by differences in the exact place of electrode position and in the electrical impedance between the muscle and the electrode wire- we defined an intra-measurement normalized index. To this end, the mean amplitude of EMG signal during spontaneous breathing was divided by the mean amplitude of EMG signal during maximal breathing effort \[[@pone.0232225.ref017]\]. This index was expected to be low under normal breathing conditions (low muscle activity in spontaneous breathing as compared with high muscle activity during maximum breathing) and increase as breathing muscles were compromised (either because high activity during spontaneous breathing as compared with maximal breathing, or because low amplitude during maximal effort when muscles approach fatigue). Hence, a higher EMG index was expected as dyspnea intensity increased.

![Example of the EMG signals from the polygraph recorder during a normalizing breathing maneuver.\
Breathing flow and EMG of diaphragm, scalene and pectoralis minor. All these signals are measured in Volts in arbitrary scale since they correspond to an uncalibrated flow signal sensed by nasal prongs and to the muscle activity EMG signals with an amplitude that depends on the amplifier gain. The first cycles correspond to spontaneous breathing and the last ones (starting at time 10 s approx.) correspond to maximum effort breathing. Increase in flow amplitude was associated with augmented respiratory muscles activity.](pone.0232225.g002){#pone.0232225.g002}

Statistical analysis {#sec006}
--------------------

Categorical variables are presented in absolute number and percentage and were analyzed with the Chi-Squared test. Continuous variables are expressed as mean ± standard deviation or median and 25--75% percentiles and were analyzed using ANOVA repeated measurements test, or Kruskal-Wallis test in case that the Shapiro-Wilk test indicated that variables were not normally distributed. Relationship between variables was measured by the coefficient of linear correlation. Assessment of changes in dyspnea score along days and muscle activity index as a function of score in dyspnea was carried out by Kruskal Wallis test and ANOVA trend analysis, respectively. Statistical analysis was performed with Stata/IC version 15.1. Statistical significance was considered for p \< 0.05.

Results {#sec007}
=======

The study was carried out on 25 patients (44% women) who, on average, were 79 years old and presented a mean ejection fraction of 46%, with preserved ejection fraction (EF \>50%) in 45% of them. [Table 1](#pone.0232225.t001){ref-type="table"} describes the main anthropometric and clinical patient data.

10.1371/journal.pone.0232225.t001

###### Baseline clinical and demographic characteristics of heart failure patients.

![](pone.0232225.t001){#pone.0232225.t001g}

  Variables                                Value
  ---------------------------------------- ---------
  *N*                                      25
  Women                                    11 (44)
  Age, years                               79 ± 10
  Active smoker                            3 (12)
  Heart failure within 12 months           8 (32)
  Heart failure within 30 days             4 (29)
  Ejection fraction, %                     46 ± 14
  Reduced LVEF (LVEF \<50%)                12 (55)
  Atrial fibrillation                      16 (64)
  Coronary artery disease                  10 (40)
  Moderate to severe valve heart disease   14 (56)
  Chronic kidney disease                   18 (75)
  Anemia                                   14 (58)
  Medication                               
   Beta-blocker                            21 (84)
   ACE inhibitor-ARB/MRA/ARNI              12 (48)
   Mean oral furosemide dose, mg           80 ± 40
   Hydrochlorothiazide                     4 (16)

Data are n (%) or mean ± standard deviation. Anemia was defined as a hemoglobin \< 13 g/dL in men and \< 12 mg/dL in women. Chronic kidney disease was defined as an estimated Glomerular Filtration Rate (eGFR) \< 60 mL/min/1.73m^2^. ACE = Angiotensin Converting Enzyme; ARB = Angiotensin Receptor Blocker; MRA = Mineralocorticoid Receptor Antagonist; ARNI = Angiotensin Receptor Neprilysin Inhibitor.

The first, second and third EMG measurements were carried out at 18 ± 5 h, 43 ± 7 h and 112 ± 22 h after admission into the Emergency Department, respectively. [Table 2](#pone.0232225.t002){ref-type="table"} shows the evolution of clinical and analytical parameters along the whole measurement period. As expected from patients successfully treated for an acute HF episode, we observed a decrease in respiratory and heart rate and, at day 5, only one third of patients needed oxygen supplementation. Renal function was stable and there was a slight increase in blood sodium, reflecting good response to treatment and decrease in volume overload. Although not measured in all patients, NT-proBNP decreased by more than 30% reflecting good response to therapy and improved prognosis. Consistently, dyspnea score decreased along the three measured days: from a median 2 (1--3) in day 1 to a median 1 (1--2) in day 5 (p = 0.021). Noteworthy, respiratory rate did not show a significant relationship with dyspnea score (p = 0.401).

10.1371/journal.pone.0232225.t002

###### Changes in clinical and analytical parameters along measurements.

![](pone.0232225.t002){#pone.0232225.t002g}

  Variables                                                First measurement    Second measurement   Third measurement   p
  -------------------------------------------------------- -------------------- -------------------- ------------------- ---------
  Routine observations                                                                                                   
   SBP, mmHg                                               119 ± 17             122 ± 22             117 ± 21            0.636
   DBP, mmHg                                               65 ± 12              62 ± 14              64 ± 15             0.916
   Heart rate, bpm                                         81 ± 17              75 ± 14              72 ± 11             0.005
   Respiratory rate (RR), bpm                              25 ± 6               20 ± 7               18 ± 5              \<0.001
   Tachypnea (RR \>25 bpm)                                 10 (40)              4 (17)               4 (17)              0.089
   Oxygen saturation, %                                    95 ± 3               95 ± 2               95 ± 3              0.903
   Oxygen therapy                                          20 (80)              15 (60)              8 (32)              \<0.001
  Blood parameters                                                                                                       
   Creatinine, mg/dL                                       1.27 ± 0.41          1.25 ± 0.38          1.25 ± 0.38         0.900
   Urea, mg/dL                                             66 ± 31              75 ± 31              71 ± 24             0.255
   eGFR, mL/min/1.73m^2^                                   53 ± 20              53 ± 19              53 ± 19             0.677
   Sodium, mEq/L                                           139.9 ± 3.0          141.0 ± 3.6          141.4 ± 3.6         0.039
   Potassium, mEq/L                                        4.14 ± 0.48          3.75 ± 0.39          4.13 ± 0.39         0.981
   NT-proBNP, pg/mL[\*](#t002fn002){ref-type="table-fn"}   7396 (3367--15066)   3853 (1616--8423)    3333 (1534--5038)   0.002

Data are n (%), mean ± standard deviation or median (interquartile range). SBP = Systolic Blood Pressure; DBP = Diastolic Blood Pressure; eGFR = estimated Glomerular Filtration Rate.

\* NT-proBNP was only measured in 12 patients at Day 2 and 19 patients at Day 5.

Out of the total 75 possible measurements per muscle (25 patients x 3 days/patient), reliable EMG results were obtained in 66 cases (88%) for diaphragm and pectoralis minor and in 55 cases (73%) in scalene. The activity of the scalene (but not of the pectoralis minor) as measured by surface EMG was significantly correlated with that of the diaphragm (r = 0.53; p \< 0.001). No significant correlation was observed between the breathing frequency and the diaphragm EMG activity index. The scalene and particularly the diaphragm (but not the pectoralis minor) activity measured by the EMG index showed a significant direct relationship with the clinical dyspnea index. Indeed, the coefficients of correlation between Likert 5 and scalene and diaphragm EMG were 0.45 (p = 0.002; F = 9.15) and 0.48 (p \< 0.001; F = 14.07), respectively. As illustrated by [Fig 3](#pone.0232225.g003){ref-type="fig"}, the higher the dyspnea index the higher EMG index (p \< 0.001 and p = 0.003 respectively). By contrast, the pectoralis minor muscle did not show a significant relationship with the clinical dyspnea scale.

![Diaphragm and scalene EMG activity index as a function of dyspnea (Likert 5 scale).\
EMG indices increased with dyspnea severity. Data are EMG index for measurements (all patients, all days) with a given dyspnea index value. Data are mean ± SE. See text for more details.](pone.0232225.g003){#pone.0232225.g003}

Discussion {#sec008}
==========

To the best of our knowledge this is the first study that has analyzed the relationship between surface respiratory electromyography (EMG) and dyspnea in acute HF patients. This pilot study strongly suggests that non-invasively measuring the activity of respiratory muscles is feasible in the clinical setting of acute HF patients and that increased activity of diaphragm and scalene is significantly associated with the severity of dyspnea measured by a conventional clinical questionnaire.

Surface EMG has some limitations as compared with invasive EMG based on needle electrodes directly sensing the muscle tissue. One limitation is that EMG signal amplitude depends on the electrical quality of the electrode attachment on the skin. Intra-patient variability in this interface impedance affects the EMG amplitude when repeating measurements in different days with newly placed electrodes in a given patient. Inter-patient variability may result from positioning the electrodes at slightly different positions and also by variation in the impedance from the muscle to the skin, for instance because of different amount of subcutaneous fat tissue. This type of intra- and inter-variability can be reduced by computing an EMG index including an intra-measurement normalization from maximal breathing maneuvers. Another limitation of surface EMG is that although the electrodes are placed on skin zones close to the muscle of interest to mainly capture the electric potentials from that muscle, some signal contamination by electrical activity from other muscles is possible, specifically regarding respiratory muscles. However, recent studies have provided validation data by comparing surface respiratory EMG with esophageal diaphragm EMG \[[@pone.0232225.ref018]\] and by using surface EMG to assess inspiratory effort \[[@pone.0232225.ref019]\]. Notwithstanding its limitations, surface EMG is a useful technique for clinical purposes given its non-invasiveness.

Dyspnea is defined as "a subjective experience of breathing discomfort that consists of qualitatively distinct sensations that vary in intensity" \[[@pone.0232225.ref020]\] and is the most common symptom in patients with acute HF. Thus, dyspnea relief has been frequently used as an end-point in clinical studies \[[@pone.0232225.ref001]\], but limitations should be considered \[[@pone.0232225.ref001],[@pone.0232225.ref002]\]. On the one hand, there is not a validated dyspnea scale in patients with HF \[[@pone.0232225.ref003]\]. A consensus group recommended the use of the same instrument at baseline and repeatedly thereafter over just asking the patient whether symptoms have changed or not \[[@pone.0232225.ref003]\]. On the other hand, a limitation of the use of the dyspnea scales in HF is the lack of standardization across studies. Although a proposal to standardize dyspnea measurement in acute HF has been published \[[@pone.0232225.ref003]\], studies in acute HF use different scales at different time points and how dyspnea was measured is frequently not described. Some studies assess dyspnea as early as within 1 hour of first medical evaluation \[[@pone.0232225.ref021]\] whereas others could include patients within 48 hours of hospitalization \[[@pone.0232225.ref022]\]. Our first measurement was carried out at 18 ± 5 h from admission into the Emergency Department, therefore capturing the worst possible clinical scenario. Interestingly, the severity of dyspnea according to the dyspnea scale was not severe (a median of 2 with Likert 5 scale (i.e. mildly short of breath) even in the most acute phase. However, all patients were in need of oxygen therapy and respiratory rate was high ([Table 2](#pone.0232225.t002){ref-type="table"}). These baseline characteristics were similar to other studies in acute HF \[[@pone.0232225.ref004]\]. In previous reports, only very severely baseline dyspnea was associated with dyspnea improvement by 5-point Likert Scale whereas moderately and severe dyspnea were not. In contrast, baseline dyspnea was associated with dyspnea improvement by Visual Analog Scale \[[@pone.0232225.ref004]\]. These data show that the most frequently used dyspnea scales are not interchangeable. Furthermore, not all scales have an established minimal clinically important difference \[[@pone.0232225.ref023]\] and it may be difficult to capture a meaningful change in dyspnea with the current scales available \[[@pone.0232225.ref004],[@pone.0232225.ref005]\]. Finally, psychological and emotional distress has been significantly associated with dyspnea in HF \[[@pone.0232225.ref024],[@pone.0232225.ref025]\] but these components or alterations of sensorial quality are usually nor assessed in the most commonly scales used for dyspnea assessment \[[@pone.0232225.ref006]\]. Accordingly, it is not surprising that many HF drug studies that have dyspnea relief as end points have failed to show a difference between the active drug and placebo. Whether they reflect a real lack of effect of the medication tested or the use of a suboptimal tool to assess the endpoint is unclear. Given the shortcomings of common dyspnea scales and their subjective nature, from a clinical point of view it would be useful to have an objective index that would bring additional information about dyspnea.

Since acute HF is associated with marked inspiratory dysfunction \[[@pone.0232225.ref007]--[@pone.0232225.ref010]\], we hypothesized that assessing the activity of respiratory muscles could provide a useful index associated with dyspnea in these patients. In addition to the diaphragm, which is the main inspiratory muscle, we also focused on accessory respiratory muscles since they are recruited in healthy subjects under conditions more strenuous than spontaneous breathing at rest \[[@pone.0232225.ref026],[@pone.0232225.ref027]\] as well as in patients with respiratory diseases presenting dyspnea as a prominent symptom. For example, in patients with COPD, a disease frequently associated with dyspnea both in the stable and acute phase, surface inspiratory electromyograms (EMG) of respiratory muscles have been correlated with the intensity of dyspnea and prognosis \[[@pone.0232225.ref013],[@pone.0232225.ref014]\]. Even when treatment with salmeterol-fluticasone in severe COPD was not associated with significant change in hyperinflation or pulmonary mechanics, this treatment induced a significant decrease in activity of the chest wall parasternal inspiratory muscle \[[@pone.0232225.ref028]\], suggesting that EMG could be a sensitive measure to monitor improvement in these respiratory patients. Surface EMG also correlated with breathlessness in patients with cystic fibrosis during exercise \[[@pone.0232225.ref029]\]. Another example showing a relationship between dyspnea and respiratory muscles activity is mechanical ventilation. In this setting, a strong correlation between accessory respiratory EMG activity and the severity of dyspnea was described in patients subjected to invasive pressure support ventilation \[[@pone.0232225.ref011]\]. It has also been reported that scalene EMG activity level was correlated with dyspnea intensity in subjects under non-invasive mechanical ventilation \[[@pone.0232225.ref012],[@pone.0232225.ref030]\]. The results obtained in the present study indicate that respiratory muscles EMG correlate with dyspnea not only in patients in whom breathlessness is induced by a respiratory system disease, but also in acute HF, a situation where the main cause of dyspnea is not a respiratory disorder. In particular, in our HF patients we observed a correlation between diaphragm and scalene EMGs, the two respiratory muscles that showed significant correlation with dyspnea ([Fig 3](#pone.0232225.g003){ref-type="fig"}). Interestingly, the lack of correlation observed between respiratory frequency and diaphragm EMG is consistent with our finding that breathing frequency did not depend on dyspnea score and with the fact that the breathing rate has not been previously reported as a good index to assess dyspnea.

Dyspnea, a subjective sensation experienced by patients with acute HF, is determined by both physical and psychological components which are still poorly understood. Although alteration of breathing activity is clearly accompanying the dyspneic events in HF patients, we did not expect that surface EMG of respiratory muscles provided a full assessment of dyspnea. However, the correlation we found between Likert 5 scale and diaphragm activity suggests that surface EMG could play a role as an objective tool helping to better assess dyspnea in acute HF. Interestingly, the measurement of surface EMG provided a feasible parameter with up to 88% technically correct measures overall. Notwithstanding the fact that we carried out single measurements, estimation of the EMG index could be carried out repeatedly and sequentially at different time intervals to both increase estimation robustness and provide time course monitoring. In this connection, future clinical applications could be developed for automatically monitoring patient's dyspnea, in particular at the patient's home (with potential telemetric follow-up). In fact, small, portable and relatively cheap recorders including surface EMG are currently available for home monitoring sleep apnea, and new miniaturized and wireless EMG devices are being developed \[[@pone.0232225.ref031]--[@pone.0232225.ref033]\].

This proof of concept pilot study has some limitations. It only included patients with breathlessness at inclusion but many patients with acute HF are comfortable at rest but breathless on slight exertion. However, these patients, who can account for as much as 56% of acute HF patients, have usually also been excluded from clinical trials \[[@pone.0232225.ref034]\], especially those with dyspnea improvement as an end-point. Given our small sample size, we did not attempt to assess whether EMG values can be associated with prognosis. Moreover, dyspnea was assessed by one of the most common clinical questionnaires (Likert 5). As it has been described that other usual clinical indices (such as Visual Analog Scale) are not interchangeable to assess acute HF, future studies should assess whether surface respiratory EMG captures dyspnea as compared with other clinical indices of dyspnea. The results from this pilot study also suggest to further investigating the correlation between dyspnea severity and diaphragm EMG index over time adjusting for the change in NT-pro BNP and other biomarkers. Such a mechanistic research would allow to unravel the physiological signal captured by the EMG index and to ascertain whether diaphragm involvement in HF failure is a mere consequence of hypoperfusion and/or volume overload or is mediated by HF-related proinflammatory cytokines upregulation thereby independently contributing to dyspnea in these patients. This mechanistic information would help to optimally target the patient phenotype and clinical status for potential clinical application of surface EMG to assess dyspnea in HF.

Conclusions {#sec009}
===========

Non-invasive measurement of respiratory muscles EMG is feasible in the setting of acute HF patients. Diaphragm, and less strongly scalene, EMG index showed a significant direct relationship with Likert 5 dyspnea scale. The results in this study provide a proof of concept that surface EMG index could be used as a marker of breathlessness severity and employed as a more objective end-point in acute HF trials in clinical settings as well as a potential home monitoring tool in HF patients at risk. However, more research and future clinical trials are required to substantiate the novel results obtained in this pilot study.

10.1371/journal.pone.0232225.r001
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Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors present a method to assess dyspnea. In my opinion, the manuscript could be useful in practice but my main concern is that it does not contain important information relating to methodology. I found that the manuscript fails to make a significant contribution beyond previously reported work (the manuscript just uses the different index to measure dyspnea compared to previous works).

The organization of the work is not quite good and clear. I would like to convey a few shortcomings and comments that I have seen in the manuscript:

\- Some affiliations are not in English.

\- It is not mentioned where the data can be found.

\- The introduction section needs to be revised.

\- EMG data processing is not described clearly. For example:

\- How the QRS was detected and removed?

\- How did the authors identify the activity of each respiratory muscle?

Reviewer \#2: The present study provides a proof of concept for monitoring of dyspnea condition by correlating EMG activity in respiratory muscles with the Likert 5 questionnaire for dyspnea severity. The idea sounds interesting and the paper is well-written, however, before being considered for publication some limitations need to be addressed by the authors:

1\) Abstract: authors claim that there is no instrument for objective evaluation of dyspnea, however, I think it may not be a 100% correct statement, since I could find at least one possible device to be used for this purpose through respiratory measurements. See below:

<https://breathe.ersjournals.com/content/breathe/1/2/100.full.pdf>

Authors should be careful with such claims.

2\) Protocol: The authors provided detailed descriptions for the electrode placements, however, a visual figure could help in making the process much more easy to follow.

3\) EMG data processing:

\- Line 122: Please explain the QRS complex and the procedure of removing it briefly.

\- Line 123: Why amplitude is the only feature considered here? Why not other signal-related features (e.g. peak, frequency of peaks, etc.) were not considered. Please explain.

4\) Statistical Analysis:

\- How did you decide on these tests? Did you have any assumption on the distribution of data? If yes, why do you use a non-parametric method (Kruskal Wallis test)? Please explain.

A minor comment:

Line 84: \"according the ESC \...\" should be \"according to the ESC \...\"

Reviewer \#3: The authors propose to use surface EMG of respiratory muscles as an objective way to detect and monitor short of breath for acute heart failure patients. To this end, they wanted to test the hypothesis that the severity of dyspnea is correlated to an EMG index (mean magnitude normalized by maximum muscle contraction) of respiratory muscles. They designed a procedure and collected data from 25 patients and post processed EMG data. They show that the severity of dyspnea is positively correlated with the magnitude of the EMG and concluded that this could be used as a clinical procedure.

The authors adopted similar approaches studied in the literature. The novelty of the paper is in its application with HF patients. The organization of the paper is good. The reviewer has a few comments as following:

\(1\) Could the authors include the total time needed for the procedure? Including sensor placement, skin preparation, etc.

\(2\) The interpretation of table 2 is not clear. The authors included many clinical measurements without explaining them.

\(3\) Speaking of table 2, it seems the respiratory rate would correlate well with both Likert and EMG. So why not use this variable to indicate short of breath instead of using EMG? After all, as the authors mention, EMG has so many limitations in practice.

\(4\) One of the disadvantages of surface EMG that the authors did not mention is that it registers heartbeat, as shown in figure 1. Did authors apply filters to remove/minimize this effect? Was this the reason why the authors placed all electrodes on the right side of the body?

\(5\) The statistical analysis is not complete. For linear correlation, please report the method used, normality of variables, residuals, normality of residuals, etc. In addition to P value, please also report F value.

\(6\) It\'s unclear how the technology will be used in clinic. One of the advantages to use EMG over Likert, according to the authors, is that it doesn\'t require patient cooperation. This is a little bit confusing because the procedure requires the patient to breathe at maximum effort for several cycles.

Reviewer \#4: This paper presents a study on diaphragm and scalene surface EMG signals in order to evaluate their feasibility to improve assessment of dyspnea in acute heart failure patients.

The paper is quite well written and organized, and the reported findings are interesting.

However, the reported results must be better displayed in fig. 1 (e.g. values on y axes are not displayed for both air flow and SEMG signals)

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

Reviewer \#4: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 0

24 Mar 2020

We have adapted the style to the journal requirements and modified the Funding Statement so now it reads: "The funder provided support in the form of salaries for authors \[JR\] and research materials, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section". Finally, we have modified the Competing Interests Statement: "This commercial affiliation does not alter our adherence to PLOS ONE policies on sharing data and materials".

(Please note that, in our answers, line numbers indicating changes correspond to lines in the colored marked-up version of the revised manuscript.)

REVIEWER \#1:

The authors present a method to assess dyspnea. In my opinion, the manuscript could be useful in practice but my main concern is that it does not contain important information relating to methodology. I found that the manuscript fails to make a significant contribution beyond previously reported work (the manuscript just uses the different index to measure dyspnea compared to previous works).

The organization of the work is not quite good and clear. I would like to convey a few shortcomings and comments that I have seen in the manuscript:

ANSWER: Thanks for considering that the manuscript could be useful in practice. We agree with the reviewer in that our work does not provide innovative methodology. Indeed, we have used the methods previously employed to assess surface EMG of respiratory muscles and dyspnea in patients with respiratory diseases. However, the aim novelty of our study is that we tested the hypothesis that this noninvasive tool provides an index related to dyspnea in the particular, and very clinically relevant population, of patients with heart failure.

\- Some affiliations are not in English.

ANSWER: In the revised version all affiliations are in English

\- It is not mentioned where the data can be found.

ANSWER: Thanks for noting that we forgot to provide this section:

Data availability: All the relevant data are provided within the manuscript. The participant patients did not consent to having details of their data publicly available. However, requests for access to some specific data may be directed to the email address of the corresponding author (<NFarreLopez@parcdesalutmar.cat>).

\- The introduction section needs to be revised.

ANSWER: Following the Reviewer suggestion, the Introduction section, particularly the second paragraph, has been revised.

\- EMG data processing is not described clearly. For example:

\- How the QRS was detected and removed?

\- How did the authors identify the activity of each respiratory muscle?

ANSWER: The data processing to remove the QRS noise from the signals has been explained in more detail in the revised manuscript (lines 143-146). We have also explained the signal periods used for computing EMG activity indices (lines 146-152).

REVIEWER \#2:

The present study provides a proof of concept for monitoring of dyspnea condition by correlating EMG activity in respiratory muscles with the Likert 5 questionnaire for dyspnea severity. The idea sounds interesting and the paper is well-written, however, before being considered for publication some limitations need to be addressed by the authors:

ANSWER: Thank you for your positive comments. We address the specific point you raised:

1\) Abstract: authors claim that there is no instrument for objective evaluation of dyspnea, however, I think it may not be a 100% correct statement, since I could find at least one possible device to be used for this purpose through respiratory measurements. See below:

<https://breathe.ersjournals.com/content/breathe/1/2/100.full.pdf>

Authors should be careful with such claims.

ANSWER: We agree with the Reviewer in that the short sentence in the abstract of the original manuscript may induce confusion. We have modified it (lines 26-30) to be more specific by stating that besides dyspnea questionnaires (which reflect the subjective patient sensation and are not fully validated in HF) there are no measurable physiological variables providing objective assessment of dyspnea in HF patients.

2\) Protocol: The authors provided detailed descriptions for the electrode placements, however, a visual figure could help in making the process much more easy to follow.

ANSWER: As suggested by the Reviewer, a new Figure 1 has been added in the revised manuscript.

3\) EMG data processing:

\- Line 122: Please explain the QRS complex and the procedure of removing it briefly.

ANSWER: The data processing to remove the QRS noise from the signals has been explained in more detail in the revised manuscript (lines 143-146).

\- Line 123: Why amplitude is the only feature considered here? Why not other signal-related features (e.g. peak, frequency of peaks, etc.) were not considered. Please explain.

ANSWER: We used the EMG amplitude index since this is the most commonly used single variable to capture respiratory muscles activity in similar settings (for instance in references 11 and 12). We have mentioned it in the revised manuscript (lines 146-152).

4\) Statistical Analysis:

\- How did you decide on these tests? Did you have any assumption on the distribution of data? If yes, why do you use a non-parametric method (Kruskal Wallis test)? Please explain.

ANSWER: We have provided the explanation in the revised manuscript (lines 177-178).

A minor comment:

Line 84: \"according the ESC \...\" should be \"according to the ESC \...\"

ANSWER: Done.

REVIEWER \#3:

The authors propose to use surface EMG of respiratory muscles as an objective way to detect and monitor short of breath for acute heart failure patients. To this end, they wanted to test the hypothesis that the severity of dyspnea is correlated to an EMG index (mean magnitude normalized by maximum muscle contraction) of respiratory muscles. They designed a procedure and collected data from 25 patients and post processed EMG data. They show that the severity of dyspnea is positively correlated with the magnitude of the EMG and concluded that this could be used as a clinical procedure.

The authors adopted similar approaches studied in the literature. The novelty of the paper is in its application with HF patients. The organization of the paper is good.

ANSWER: Thanks for your positive comment.

The reviewer has a few comments as following:

\(1\) Could the authors include the total time needed for the procedure? Including sensor placement, skin preparation, etc.

ANSWER: It is difficult to provide a clear answer to this question, particularly in view of potential interest for future routine applications. On the one hand, the time required for each measurement considerably depended on the specific patient and on the level of dyspnea he/she was experiencing at the moment of the measurement. On the other hand, as this was a pilot (not a routine) study, it involved a learning curve in its practical implementation and thus in the time required. Moreover, in the pilot study reported here, 3 respiratory muscles were measured in each patent. Nevertheless, any potential future application in routine would involve just monitoring one muscle EMG (diaphragm or scalene), with substantial reduction in time, particularly if the process is carried out by a specifically trained professional.

\(2\) The interpretation of table 2 is not clear. The authors included many clinical measurements without explaining them.

ANSWER: In the Results section we have now added a description of the changes observed along the study period in the most relevant clinical parameters shown in Table 2 (lines 203-208).

\(3\) Speaking of table 2, it seems the respiratory rate would correlate well with both Likert and EMG. So why not use this variable to indicate short of breath instead of using EMG? After all, as the authors mention, EMG has so many limitations in practice.

ANSWER: The breathing frequency is modified by the HF severity status, as it is well-known and as it is also reflected in Table 2 showing that breathing rate decreased along the days after admission for HF exacerbation. However, in agreement with previous studies, we found no significant relationship between breathing frequency and dyspnea score. In the revised manuscript we have reported this lack of relationship in Results (lines 209-210) and we have mentioned it in the Discussion (lines 323-324).

\(4\) One of the disadvantages of surface EMG that the authors did not mention is that it registers heartbeat, as shown in figure 1. Did authors apply filters to remove/minimize this effect? Was this the reason why the authors placed all electrodes on the right side of the body

ANSWER: In the original manuscript we very briefly mentioned that a filter for the heartbeat noise was applied. However, we have now explained the QRS filter used in more detail (lines 143-146). Yes, we placed the electrodes on the body right side to minimize the heartbeat noise into the surface EMG of respiratory muscles,.

\(5\) The statistical analysis is not complete. For linear correlation, please report the method used, normality of variables, residuals, normality of residuals, etc. In addition to P value, please also report F value.

ANSWER: Thank you for your comment. To assess the linear correlation between Likert 5 scale and EMG index we used an ANOVA trend analysis test (line 182): with a p-value less than 0.05, the null hypothesis that the variables were not linear correlated was rejected. In the revised version we included F value for correlation tests between Likert 5 scale and EMG indices (line 227).

\(6\) It\'s unclear how the technology will be used in clinic. One of the advantages to use EMG over Likert, according to the authors, is that it doesn\'t require patient cooperation. This is a little bit confusing because the procedure requires the patient to breathe at maximum effort for several cycles.

ANSWER: Thank you for your comment. Certainly, some cooperation is required from the patient. To avoid any confusion, the way we ended our final sentence in Introduction has been corrected (lines 89-90).

REVIEWER \#4:

This paper presents a study on diaphragm and scalene surface EMG signals in order to evaluate their feasibility to improve assessment of dyspnea in acute heart failure patients.

The paper is quite well written and organized, and the reported findings are interesting.

ANSWER: Thanks for your positive comment.

H

owever, the reported results must be better displayed in fig. 1 (e.g. values on y axes are not displayed for both air flow and SEMG signals)

ANSWER: Thanks for noting it. In the legend of Figure 2 (former fig.1) we have now indicated: "All these are voltage signals in arbitrary scale since they correspond to an uncalibrated flow signal sensed by nasal prongs and to the muscle activity EMG signals with amplitude that depends
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

Reviewer \#4: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#4: (No Response)

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#4: (No Response)

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#4: (No Response)

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#4: (No Response)

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: (No Response)

Reviewer \#2: (No Response)

Reviewer \#4: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).
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Reviewer \#2: No

Reviewer \#4: No
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